Kornimate/medical-research-clean huggingface dataset:
outcomes of a novel technique minimal scar mastectomy

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Summary: nipple sparing mastectomy is oncologically safe and has a good cosmetic outcome. however, nipple sparing mastectomy was conventionally performed with reconstruction. minimal scar mastectomy (msm) is a novel technique which could allow women, with non-ptotic breasts, who do not want reconstruction, to conserve their nipple areolar complex (nac) and avoid the transverse scar associated with modified radical mastectomy. this is the first study on the oncologic and surgical outcomes of msm.


Eligibility criteria:
inclusion criteria: breast cancer patients who opted for minimal scar mastectomy - exclusion criteria: breast cancer patients who underwent conventional mastectomy -

Keywords: breast cancer nipple sparing mastectomy
management of pain associated with failed back surgery syndrome

Conditions: Failed Back Surgery Syndrome

Summary: neuropathic pain is a common complication following different types of spine surgery making negative impact on health, along with life style changes and management, many neurologist prescribed either pregabalin or gabapentin to manage this condition with overall good results. our study aims to evaluate the efficacy of pregabalin and gabapentin in the management of this condition and to compare between them


Eligibility criteria:
inclusion criteria: * patients with previous spine surgery and subsequent chronic back pain exclusion criteria: * patients with connective tissue diseases * patients with psychiatric illnesses

Keywords: pregabalin gabapentin neuropathic pain spine surgery
nerve function in older diabetic patients who are undergoing chemotherapy for metastatic solid tumors

Conditions: Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: learning about the side effects of chemotherapy may help plan treatment and may help patients live more comfortably. purpose: this clinical trial is studying nerve function in older diabetic patients who are undergoing chemotherapy for metastatic solid tumors.

objectives: primary * determine changes in peripheral nerve function in older patients with diabetes and metastatic solid tumors treated with taxane or platinum-containing chemotherapy regimens. * determine the extent to which age, pre-existing diabetes mellitus, and level of glycemic control predict a differential pattern in outcome beyond the effect of the drugs in patients treated with these regimens. * develop a clinical assessment that would predict whether or not patients with diabetes mellitus are more or less susceptible to the neurotoxic effects of chemotherapy. outline: this is a longitudinal study. patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control. patients are evaluated at baseline, every 3 weeks during chemotherapy for up to 4 treatments, and at 2 months after completion of treatment. projected accrual: a total of 50 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of solid tumor * metastatic disease (stage iv) * planning neoadjuvant or adjuvant treatment of locoregional definitive or systemic therapy comprising ≥ 1 of the following: * taxane (paclitaxel or docetaxel) * platinum (cisplatin, carboplatin, or oxaliplatin) * diagnosis of type i or ii diabetes mellitus patient characteristics: performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * no other disease that reduces peripheral nerve function (e.g., hiv/aids, uremia, spinal injuries, alcoholism, or cns problems) prior concurrent therapy: chemotherapy * see disease characteristics * no prior chemotherapy * no prior or concurrent neurotoxic drugs (i.e., vincristine)

Keywords: neurotoxicity unspecified adult solid tumor, protocol specific
early versus late sustained low efficiency dialysis in critically ill cirrhotics with septic shock and acute kidney injury

Conditions: Cirrhotics With Septic Shock and Acute Kidney Injury

Summary: consecutive patients with cirrhosis and septic shock with aki who give written informed consent will be included in this prospective trial. at baseline nt-pro bnp, urine n-gal will be done for all patients. a baseline serum blood sample (10 ml) and urine sample will be stored. septic shock will be defined by the presence of two or more diagnostic criteria for the systemic inflammatory response syndrome, proven or suspected infection with hypotension non-responsive to adequate fluid resuscitation assessed by no evidence of stroke volume variation on flow track and need of a vasopressor to achieve a target mean arterial pressure (map) of ≥ 65 mm hg. a record of cvp, ivc diameter and b-lines on ultrasound lung would also be done. patients with age less than 18 years, severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, copd) pregnancy, chronic kidney disease on hemodialysis, patients already meeting emergency criteria for immediate hemodialysis at the time of randomization as specified in the late group, patients transferred from other hospitals who have already been on hemodialysis before their arrival in the intensive care unit, extremely moribund patients with an expected life expectancy of less than 24 hours, failure to give informed consent from family members.


Eligibility criteria:
inclusion criteria: - patients with cirrhosis with septic shock associated aki (acute kidney injury) stage 3 akin/kdigo stage 2. exclusion criteria: * patients with age less than 18 years * severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, coronary obstructive pulmonary disease) * pregnancy * chronic kidney disease on hemodialysis * patients with hepatorenal syndrome, post renal obstructive aki, aki due to suspected based on history,urinalysis and past clinical records-glomerulonephritis, interstitial nephritis or vasculitis * patients already meeting emergency criteria for immediate hemodialysis at the time of randomization as specified in the late group (serum potassium\>6 meq/lt, metabolic acidosis ph\<7.12, acute pulmonary edema, severe volume overload with hypoxemia non-responsive to diuretic treatment) * patients transferred from other hospitals who have already been on hemodialysis before their arrival in the intensive care unit * extremely moribund patients with an expected life expectancy of less than 24 hours * failure to give informed consent from family members. * hemodynamic instability requiring very high dose of vasopressors
scube-1 and vap-1 levels on diagnosis pulmonary embolism

Conditions: Pulmonary Embolism Acute

Summary: acute pulmonary thromboembolism is a life-threatening disease. clinical suspicion is essential for diagnosis because of lack of a specific finding for diagnosis of pte. the aim of this study is to investigate the relationship between the diagnosis and prognosis of alternative biomarkers such as scube-1 and vap-1 in the diagnosis of clinically suspected acute pte. patients who were admitted to the emergency department and diagnosed as acute pte were included in the study. patients with acute ischemic disease, liver failure, renal failure, pregnancy, active malignancy and/or history of known pte were excluded from the study. a control group was formed from healthy volunteers at similar age and sex. scube-1 and vap-1 levels were studied from serum samples taken from the patient and control groups. data were analyzed using by ibm spss v23.

the definitive diagnosis of apt is made by ventilation/perfusion (v/q) scintigraphy and thorax computed tomography angiography (cta). there is no specific examination as a laboratory parameter. a definitive diagnosis cannot be made with d-dimer, which is the most frequently used laboratory test today; it is used to exclude the diagnosis of apt. the non-specificity of the clinical picture, the fact that the diagnosis depends on the experience of the physician and the necessity of exposure to radiation and contrast material for the definitive diagnosis has revealed the necessity of searching for alternative ways for the diagnosis of apt. "signal peptide cub-egf domain-containing protein-1" (scube-1) is a biomarker released during platelet aggregation, and "vascular adhesion protein-1" (vap-1) is a biomarker released from endothelium, and these biomarkers show promise for the diagnosis of apt. determination of serum scube-1 and serum vap-1 levels 5 ml blood taken from the peripheral veins of the patients was placed in a biochemistry tube and centrifuged at 3000 g. after centrifugation, the serum part of the blood was separated and taken into an eppendorf tube and stored in an ultra-deep freezer at minus 80°c until the study day. before starting the study, the elisa kits kept at 2-8°c and the samples kept in an ultra-deep freezer at minus 80°c were brought to room temperature.

Eligibility criteria:
inclusion criteria: * being older than 18 years of age * presenting to the emergency department, * diagnosed with acute pte by contrast-enhanced computed tomography angiography exclusion criteria: * having acute ischemic disease, liver, kidney or advanced heart failure, liver disease, pregnancy, active malignancy or hematological disease, and a known history of pte.

Keywords: scube-1 vap-1 pulmonary embolism
efficacy of guided biofilm therapy (gbt) for treatment of deep periodontal pockets.

Conditions: Periodontitis

Summary: the aim of the study is to evaluate the efficacy of guided biofilm therapy (gbt) for treatment of deep periodontal pockets. the objectives are 1- to compare the change in the clinical periodontal parameters and microbiological parameters by using real time pcr for p. gingivalis, aggregatibacter actinomycetemcomitans and filifactor alocis among sites treated by gbt and conventional hand instrumentation after a period of 3 months and to assess the level of the selected periodontal pathogens in deep periodontal pockets and to estimate and compare deep periodontal pockets which need surgery after 3 months of non-surgical treatment by gbt and conventional hand instrumentation. the hypothesis is whether there are no differences in in the clinical and microbiological parameters among sites treated by gbt and conventional hand instrumentation after a period of 3 months or there are differences in in the clinical and microbiological parameters among sites treated by gbt and conventional hand instrumentation after a period of 3 months. the participants will be selected on a consecutive basis from patients referred to the department of periodontics, college of dentistry, university of baghdad. for each patient, each site will be randomly assigned to either treatment protocol: 1. sites treated with gbt. 2. sites treated with conventional manual instrumentation only.


Eligibility criteria:
inclusion criteria: 1. adult patients, aged more than 18 years. 2. no history of any systemic diseases. 3. diagnosed with stages 3 and 4 periodontitis according to the 2017 world workshop on the classification of periodontal disease. 4. the presence of deep periodontal pocket ≥ 6 mm in two non-adjacent teeth. exclusion criteria: 1. smokers. 2. pregnant and lactating mothers. 3. history of any previous subgingival instrumentation in the last 3 months. 4. the use of antibiotics/non-steroidal anti-inflammatory drugs in the last 3 months. 5. regular use of medication to control systemic illness. 6. the presence of perio-endo lesion.
long term safety of sl77.0499-10 (alfuzosin) in patients with bph

Conditions: Benign Prostatic Hyperplasia

Summary: primary: to assess the safety of sl77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to bph. secondary: * to provide the information on the efficacy of sl77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to bph. * to document the plasma concentration of sl77.0499-10 after repeated administration of sl77.0499-10 10mg administered once daily in patients with lower urinary tract symptoms related to bph.


Eligibility criteria:
inclusion criteria: * having a symptomatic bph diagnosed clinically by digital rectal examination and ultrasonography * suffering for at least 6 months from lower urinary tract symptoms related to bph * an i-pss total score ≥ 13 * out patient exclusion criteria: * patients previously treated with sl77.0499-10. * neurogenic bladder dysfunction, confirmed or suspected, irrespective of aetiology. * isolated bladder neck disease. * diagnosed carcinoma of the prostate. * previous prostatic surgery or other invasive procedures (thermotherapy...) for the treatment of bph. * patients having an indwelling catheter. * a residual urine \> 200ml. * patients with moderate or sever hepatic insufficiency. * known hypersensitivity to alpha1-blockers. * patients who have received anti-androgens, 5alpha-reductase inhibitors, lh-rh analogues within the previous 3 months before screening * patients judged inappropriate for admission to the study by the investigator or the sub-investigator.

Keywords: benign prostatic hyperplasiam adrenergic alpha-antagonist
bio-feedback to improving stability in elderly population

Conditions: Parkinson's Disease Patients

Summary: our hypothesis is that intensive training with positive biofeedback may enhance postural control and stability in parkinson's disease patients and in elderly fallers.

the aim of the study is to treat parkinson's patients and elderly fallers. the intervention is intensive training with biofeedback to try to correct stooped posture, and to improve stability in standing and in walking.

Eligibility criteria:
inclusion criteria: * idiopathic pd for \>2 yrs * between 50-90 yrs * on anti-parkinsonian medication * hoehn \& yahr 2-3 in "on" * free of serious co-morbidities * able to walk but reports difficulties in gait * can use assistive device exclusion criteria: * significant orthopedic disturbances or pain * major depression (dsm iv) * dementia (mmse\<24) * clinically significant hearing problems * unstable medical condition (2 wks from meds change) * deep brain stimulation

Keywords: parkinson's disease audio feedback postural control
functional electrical stimulation on functional rehabilitation in children with erb's palsy

Conditions: Erb's Palsy

Summary: erb's palsy is a type of brachial plexus injury occurs in infants due to injury of nerves during childbirth. injury causes weakness or paralysis of different muscles. different type of approaches are made for the treatment of erb;s palsy such passive range of motion, stretching ,splinting ,electrotherapy etc. in erb's palsy the most affected ranges are shoulder abduction and shoulder external rotation. quasi experimental study will be done on the patient with erb's palsy intervention applied will be functional electrical stimulation (a low frequency current) applied 5 day a weeks for 2 weeks than on alternate days for the rest of the treatment. setting for functional electrical stimulation will be frequency 20 pps with pulse width of 300 msec. 18 patient will be recruited . "assumed population standard deviation"4.24" "confidence level""0.95" "acceptable error""2". pre-intervention reading will be taken on modified mallet scale and universal goniometer and post intervention measurement will be taken after 02, 04 ,06 months.


Eligibility criteria:
inclusion criteria: * diagnosed with erb's palsy * children of age 15 months to 3 years exclusion criteria: * hemiplegic cerebral palsy * children with upper limb fractures * obstetrical brachial plexus injury * upper limb contracture
retrospective data analysis on the application of swan-ganz catheter in cardiac surgery

Conditions: Postoperative Complications

Summary: the investigators aimed to investigate postoperative complications associated with swan-ganz catheter based on the clinical data of wuhan union hospital and wuhan asian heart hospital for 10 years, including major cardiovascular, respiratory adverse events, icu time, mechanical ventilation time, length of hospital stay, in-hospital mortality, and 30-day postoperative mortality events.


Eligibility criteria:
inclusion criteria: * over 18 years old; * patients undergoing major cardiac surgery under general anesthesia; * patients with complete sex, age, use of floating catheter and prognosis data exclusion criteria: * asa grade v and above; * end stage renal disease requiring (or undergoing) renal replacement therapy; * pregnant or lactating women

Keywords: swan-ganz catheter cardiac surgery postoperative complications
prosthetic maintenance of two implant-retained overdentures reinforced with pekk versus co-cr frameworks

Conditions: Completely Edentulous

Summary: the goal of this randomized clinical trial is to compare and assess the prosthetic maintenance of two implant-retained mandibular overdentures reinforced with pekk and co-cr frameworks after twelve months. twenty-four participants were randomly assigned to two groups: group i received a mandibular implant-retained overdenture reinforced with a co-cr framework, while group ii received a mandibular implant-retained overdenture reinforced with a pekk framework. also, both groups were rehabilitated with a maxillary complete removable denture.

twenty-four participants with edentulous maxillary and mandibular ridges underwent meticulous selection, with two implants placed in the mandibular canine areas through a two-stage surgical technique facilitated by a radiographic and surgical stent. following this, patients were provided with maxillary and mandibular complete removable dentures relined with soft liners. after the subsequent three-month osseointegration period, ball attachments were introduced. patients were randomly allocated to two groups based on the type of prosthesis they received. group i received mandibular implant-retained overdenture reinforced with the co-cr framework, while group ii received mandibular implant-retained overdenture reinforced with the pekk framework, both groups received complete removable dentures for the maxillary arch. the assessment of prosthetic maintenance for mandibular implant-retained overdentures in both groups was conducted twelve months post-denture insertion.

Eligibility criteria:
inclusion criteria: * age range between 50-70 years old. * completely edentulous patients * systemically free from any disease that contraindicates implant placement. * a minimum of 12 -15 millimeters of bone height and 6 mm bone width at canine areas diagnosed from the pre-operative cone beam ct. * sufficient inter-arch space (15mm) to accommodate the mandibular implant-retained overdentures. exclusion criteria: * patients with bone or mucosal diseases. * heavy smokers. * patients with uncontrolled metabolic disorders such as diabetes mellitus. * patients with parafunctional habits. * patients with conditions that might complicate the treatment, such as: severe gag reflex, limited mouth opening.

Keywords: dental implants maintenance/standards overdenture
glycoprotein iib/iiia inhibitors versus standard therapy in patients with myocardial infarction and no-reflow

Conditions: Acute Myocardial Infarction

Summary: aim of the study is to examine the effects of glycoprotein iib/iiia inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.


Eligibility criteria:
inclusion criteria: * st-elevation myocardial infarction and non-st-elevation myocardial infarction \<48 h after symptom onset * angiographic evidence of no-reflow (thrombolysis in myocardial infarction-flow grade ≤2) after primary percutaneous coronary intervention * age ≥18 years * informed consent exclusion criteria: * st-elevation myocardial infarction and non-st-elevation myocardial infarction patients with thrombolysis in myocardial infarction-flow 3 after primary percutaneous coronary intervention * age ≤18 years * known pregnancy, breast-feeding or intend to become pregnant during the study period * contraindication for treatment with platelet inhibitors * known allergy to glycoprotein iib/iiia inhibitors, aspirin, or heparin * active peptic gastric or duodenal ulcer * history of major surgery (including intracranial or intraspinal) \<4 weeks * active bleeding or bleeding diathesis * stroke \<2 years (ischemic and hemorrhagic) * known coagulation defect or relevant thrombocytopenia * arteriovenous malformations or aneurysm * severe liver insufficiency * renal insufficiency requiring dialysis * uncontrolled hypertension * hypertensive retinopathy * vasculitis * fibrinolysis \<12 hours * contraindication for cardiac magnetic resonance imaging at study entry * patients without informed consent * participation in another trial
viennese prevalence study of anderson-fabry disease

Conditions: Fabry Disease; Left Ventricular Hypertrophy

Summary: the prevalence of anderson - fabry disease in patients with left ventricular hypertrophy is unclear. the investigators will examine urine - α - galactosidase activity and globotriaosylceramide isoforms in these patients.

anderson - fabry disease (afd) is a rare, x - linked hereditary systemic lysosomal storage disorder which usually affects the heart. the reported incidence of afd is between 1 in 117000 and 1 in 240000 live births. due to a deficiency of the enzyme α - galactosidase, glycosphingo-lipids, primarily globotriaosylceramide, are stored also in endothelial and myocardial cells, leading to morphologic and functional changes. afd-cardiomyopathy progresses with age and with the course of the disease, leading to reduced life expectancy. the investigators hypothesize, that afd could be underdiagnosed in patients with only mild or moderate left ventricular myocardial hypertrophy. early diagnosis of afd may be relevant since affected patients might benefit from enzyme replacement therapy at early stage of disease. the investigators will examine 4000 consecutive patients with an echocardiographically measured interventricular septum thickness of ≥ 12mm. urine samples will be collected and gb3-isoforms, creatinine and α - galactosidase activity will be measured.

Eligibility criteria:
inclusion criteria: * patients with myocardial septum wall thickness ≥ 12mm exclusion criteria: * patients \< 18 years * patients unable to provide urine sample

Keywords: hereditary anderson-fabry prevalence heart hypertrophy urine globotriaosylceramide isoforms α - galactosidase